NY-AQARA
23.11.2022 09:01:38 CET | Business Wire | Press release
Aqara, a leading provider of smart home products, introduces its new Cube T1 Pro, which is the updated version of its iconic wireless Cube controller. Built upon the success of its predecessor, the new cube adds HomeKit and Alexa support1, so that it can be used to control a wide range of smart home devices within both ecosystems. Moreover, it adds the new Scene Mode to allow users to use not only actions but also different sides of the cube to activate smart home scenes or devices2. The Cube T1 Pro is now available on Aqara Amazon brand stores in North America (US, Canada) and Europe (France, Germany, Italy, Spain, UK), and via selective Aqara retailers worldwide.
Similar to its predecessor, the Cube T1 Pro recognizes different actions such as push, shake, rotate, flip and tap. A new Scene Mode is added, and when the mode is activated the cube also recognizes different sides, so that users can simply use each side to control various scenes and devices. Dice-like indicators are printed on the sides to help users distinguish one from the others. Moreover, thanks to this new mode the Cube T1 Pro can be used in both HomeKit and Alexa. It’s also expected to support Matter via the Aqara hubs through an OTA update, and the Hub M2 will be the first hub to receive such update.
With all these improvements, the Cube T1 Pro enables a more intuitive way to control a smart home2. For instance, users can activate the Morning Routine by flipping it to Side 1, and trigger the Home Cinema Scene by flipping it to Side 2. Additionally, it’s now possible within the Aqara Home app to control more than one sets of curtains, roller shades or lights by rotating the new cube. For example, flipping it to Side 3 and rotating the cube to adjust the open percentage of the curtains, and flipping it to Side 4 and rotating to dim the Aqara lights3. The versatility of this cube controller allows users to be creative with their smart home setups.
Based on the Zigbee 3.0 protocol which allows faster response, higher reliability, better compatibility and improved energy efficiency, the Cube T1 Pro has a battery life of up to 2 years. It also supports OTA updates, which means that new features and fixes can be added to the new cube after the its initial release.
In celebration of the launch, Aqara now offers a 10% discount for the new cube on its Amazon stores. North American customers will enjoy the offer with the promo code NACUBET1 in the US and Canada, while European customers will enjoy it using the promo code CBT1PROEU in France, Germany, Italy, Spain and the UK. Both codes can be combined with coupon, and will be valid through November 24, 2022.
For more details of the Cube T1 Pro, please visit our website.
- A Zigbee 3.0-based Aqara hub is required. The Cube T1 Pro is recognized as 6 wireless buttons in HomeKit, and as 6 motion sensors in Alexa.
- A Zigbee 3.0-based Aqara hub is required.
- The compatible Aqara lights, Curtain Driver E1 or Roller Shade Driver E1 are required.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221123005015/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom